06.26.18
Graham Brearley, Ph.D., has been appointed general manager of Catalent Pharma Solutions Madison, WI facility. He will report to Brian Riley, vice president of operations, Biologics & Specialty Drug Delivery.
Dr. Brearley most recently served as senior director, Technical Operations with Shire, where he was responsible for leading strategy, organization, execution and business processes. He has provided technical expertise on operational aspects of the bioscience business, including process development and life cycle management, for more than 25 years. Prior to that, Dr. Brearley held leadership positions at organizations including Sigma-Aldrich and Baxter.
Opened in April 2013 and recently expanded, Catalent Biologics’ Madison facility provides development, manufacturing and analytical services for new biological entities and biosimilars, and leverages its proprietary GPEx cell line technology, used to create high-yielding mammalian cell lines. The Madison facility was designed for flexible cGMP production, from 10 to 4,000-liter scale, and non-GMP production up to 250-liter scale, and features single-use technologies and unidirectional flow to maximize efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.
Dr. Brearley most recently served as senior director, Technical Operations with Shire, where he was responsible for leading strategy, organization, execution and business processes. He has provided technical expertise on operational aspects of the bioscience business, including process development and life cycle management, for more than 25 years. Prior to that, Dr. Brearley held leadership positions at organizations including Sigma-Aldrich and Baxter.
Opened in April 2013 and recently expanded, Catalent Biologics’ Madison facility provides development, manufacturing and analytical services for new biological entities and biosimilars, and leverages its proprietary GPEx cell line technology, used to create high-yielding mammalian cell lines. The Madison facility was designed for flexible cGMP production, from 10 to 4,000-liter scale, and non-GMP production up to 250-liter scale, and features single-use technologies and unidirectional flow to maximize efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.
